Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 4,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Head Clear all
Completed Not applicable Interventional

IIT2020-20-SHIRAZIP-WALK: Nature Walks

NCT04896580
View directory record Official record
Conditions
Breast Cancer, Cancer, Lymphoma, Leukemia, Prostate Cancer, Thyroid Cancer, Hematologic Malignancy, Non-hodgkin Lymphoma
Interventions
Nature based exercise
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 19, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

NCT02542215
View directory record Official record
Conditions
Oral Mucositis
Interventions
Cobiprostone, Placebo, Standard Care - Chemotherapy, Standard Care - Radiation
Drug · Radiation
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
76
States / cities
Birmingham, Alabama • Peoria, Arizona • Yuma, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 19, 2026, 4:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

NCT03474497
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IL-2, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 19, 2026, 4:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

NCT02452424
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions
PLX3397, Pembrolizumab
Drug · Biological
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 19, 2026, 4:05 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

NCT04681248
View directory record Official record
Conditions
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma, Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma, Gastric Cancer
Interventions
DKN-01
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 19, 2026, 4:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 19, 2026, 4:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions
MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Drug · Combination Product
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Not applicable Interventional

The Effect of Screen Time on Recovery From Concussion

NCT03564210
View directory record Official record
Conditions
Concussion, Brain
Interventions
Screen time permitted, Screen Time Abstain
Behavioral
Lead sponsor
Theodore Macnow
Other
Eligibility
12 Years to 25 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Not applicable Interventional

Couple-Based Intervention for Patients With Head and Neck Cancer and Their Partners

NCT01785576
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Couple-Based CBT Intervention
Behavioral
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 19, 2026, 4:05 AM EDT
Completed No phase listed Observational

Concussion in Motor Vehicle Accidents: The Concussion Identification Index

NCT02858544
View directory record Official record
Conditions
Motor Vehicle Accidents, TBI (Traumatic Brain Injury), Brain Contusion, Brain Injuries, Cortical Contusion, Concussion Mild, Cerebral Concussion, Brain Concussion, Accidents, Traffic, Traffic Accidents, Traumatic Brain Injury With Brief Loss of Consciousness, Traumatic Brain Injury With no Loss of Consciousness, Traumatic Brain Injury With Loss of Consciousness
Interventions
The Concussion Identification Index, ImPACT
Other
Lead sponsor
Clionsky Neuro Systems Inc.
Industry
Eligibility
10 Years to 60 Years
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00700063
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Topical Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Hot Springs, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 19, 2026, 4:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07038343
View directory record Official record
Conditions
Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions
AVZO-1418, Combination Agent 1, Combination Agent 2
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Not applicable Interventional

Care for Post-Concussive Symptoms

NCT02268240
View directory record Official record
Conditions
Concussion
Interventions
Stepped Care
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 19, 2026, 4:05 AM EDT
Completed No phase listed Observational

Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making

NCT03239834
View directory record Official record
Conditions
Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral, Tongue Neoplasms, Oropharyngeal Neoplasms, Oral Ulcer
Interventions
OncAlert
Device
Lead sponsor
Vigilant Biosciences, Inc.
Industry
Eligibility
23 Years and older
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Beverly Hills, California • La Mesa, California • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 19, 2026, 4:05 AM EDT
Recruiting Phase 3 Interventional

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864
View directory record Official record
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
volrustomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott Valley, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 4:05 AM EDT
Not listed No phase listed Observational

E-MAX 2nd Gen Vit E Poly On BIOLOX Delta Ceramic Heads

NCT01943149
View directory record Official record
Conditions
In Need of a Total Hip Arthroplasty
Interventions
Not listed
Lead sponsor
Renovis Surgical Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

NCT02423863
View directory record Official record
Conditions
Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
Interventions
Hiltonol
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Chevy Chase, Maryland • Easton, Maryland • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 19, 2026, 4:05 AM EDT
Active, not recruiting No phase listed Observational

Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors

NCT00581906
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DCE-MRI, DW-MRI and MRS
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

Celecoxib in Treating Patients With Precancerous Lesions of the Mouth

NCT00014404
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
celecoxib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

NCT00004233
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, triacetyluridine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
97
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 19, 2026, 4:05 AM EDT
Withdrawn Not applicable Interventional

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

NCT00038038
View directory record Official record
Conditions
Squamous Cell Carcinoma, Head and Neck Neoplasms, Metastases, Neoplasm
Interventions
18F-fluoromisonidazole, PET scan
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.

NCT03617926
View directory record Official record
Conditions
Head Lice, Pediculosis Capitis
Interventions
X92001666, RID shampoo
Device · Other
Lead sponsor
Oystershell NV
Industry
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 19, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

NCT01927744
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Erlotinib, Placebo, Questionnaires, Phone Call, Chemotherapy
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 4:05 AM EDT